At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 182 enrolled
Drug / intervention
LYR-210 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
In Brief
A Phase 3 clinical trial evaluating LYR-210, Sham procedure control, and 1 other intervention for Chronic Sinusitis and Chronic Rhinosinusitis (Diagnosis). Completed, enrolled 182 participants across 57 sites in 6 countries.
Detailed Summary
Multicenter, phase III, randomized, blinded, controlled, parallel group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Bulgaria, Germany, Hungary, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMay 2022
Primary CompletionApr 2025
TodayJul 2026
First PostedMar 25, 2022
Enrollment StartMay 13, 2022
Primary CompletionApr 2, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.3 years ago
Interventions
LYR-210drug
LYR-210 drug matrix (mometasone furoate)
Sham procedure controldrug
Sham procedure control
Background therapyother
Daily Saline Irrigation